Abuse of alcohol (ethanol) during pregnancy has been linked to a wide range of birth-related defects collectively known as Fetal Alcohol Spectrum Disorders (FASD), which are characterized by an array of developmental defects include craniofacial and cardiac malformations. Prenatal alcohol exposure also impairs the development of central nervous system (CNS) leading to several abnormal behaviors in the offspring including vulnerability to alcohol abuse. It remains a significant clinical challenge and an important social problem. Although interventions for specific outcomes are now emerging, there are currently no clinical therapies for the treatment of global fetal alcohol effects. In spite of some progress in delineating the mechanisms contributing to FASD, gaps in our knowledge still largely remain. The recently discovered endocannabinoid system has become a focus of intense research in understanding its significance in health and disease. There is accumulating evidence now implicating a role of the endocannabinoid system in several neuropsychiatric disorders including alcohol related behavior. Our preliminary studies indicate selective abnormalities in the components of endocannabinoid system in the striatum and a greater alcohol drinking behavior in utero alcohol exposed adolescent offspring mice. Based on these evidences and our preliminary findings, we hypothesize that alcohol exposure during critical periods of gestation adversely affects the endocannabinoid system, one among many other targets, leading to increased alcohol drinking behavior in the offspring. To our knowledge, this would be the first study to explore a role of the endocannabinoid system in the neurobiology of FASD. The proposed study will use a well-established alcohol binge model of FASD, in which the pregnant C57BL/6J mice will be given alcohol (2.9 g/kg twice daily, i.g.) on gestation days 7 and 8. The effect of alcohol exposure on the endocannabinoid system will be examined in the brain of offspring at adolescence and adult PD45 and PD90. This study will further evaluate whether prenatal alcohol exposure lead to an abnormal alcohol drinking behavior in offspring and if so, it is regulated by the endocannabinoid system. The proposed study is timely and findings may have a great potential in the development of therapeutic intervention in the treatment of behavioral deficits associated with prenatal alcohol exposure.

Public Health Relevance

Abuse of alcohol during pregnancy has become a major health and social concern. The current proposal focuses on understanding a role of the endocannabinoid system in relation to neurochemical and behavioral changes resulting from prenatal alcohol exposure. The long-term goal of this study is to understand the cellular and molecular mechanism/s of FASD, especially alcohol-related behavior in offspring and to evaluate possible utility of the endocannabinoid system as a therapeutic target for the treatment of behavioral deficits associated with FASD.

Agency
National Institute of Health (NIH)
Institute
National Institute on Alcohol Abuse and Alcoholism (NIAAA)
Type
Exploratory/Developmental Grants (R21)
Project #
5R21AA018709-02
Application #
8204435
Study Section
Health Services Research Review Subcommittee (AA)
Program Officer
Hereld, Dale
Project Start
2010-12-05
Project End
2013-11-30
Budget Start
2011-12-01
Budget End
2013-11-30
Support Year
2
Fiscal Year
2012
Total Cost
$187,625
Indirect Cost
$68,875
Name
Nathan Kline Institute for Psychiatric Research
Department
Type
DUNS #
167204762
City
Orangeburg
State
NY
Country
United States
Zip Code
10962
Balla, Andrea; Dong, Bin; Shilpa, Borehalli M et al. (2018) Cannabinoid-1 receptor neutral antagonist reduces binge-like alcohol consumption and alcohol-induced accumbal dopaminergic signaling. Neuropharmacology 131:200-208
Psychoyos, Delphine; Vinod, K Yaragudri (2013) Marijuana, Spice 'herbal high', and early neural development: implications for rescheduling and legalization. Drug Test Anal 5:27-45
Psychoyos, Delphine; Vinod, K Yaragudri; Cao, Jin et al. (2012) Cannabinoid receptor 1 signaling in embryo neurodevelopment. Birth Defects Res B Dev Reprod Toxicol 95:137-50